3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
122
Lung Neoplasms
49
Triple Negative Breast Neoplasms
35
Breast Neoplasms
33
Small Cell Lung Carcinoma
29
Squamous Cell Carcinoma of Head and Neck
24
Ovarian Neoplasms
24
Neoplasm Metastasis
21
Fallopian Tube Neoplasms
19
Endometrial Neoplasms
19
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Neoplasms
15
Head and Neck Neoplasms
12
Colorectal Neoplasms
11
Carcinoma
10
Oropharyngeal Neoplasms
9
Esophageal Neoplasms
9
Urinary Bladder Neoplasms
8
Prostatic Neoplasms
8
Carcinoma, Transitional Cell
8
Pancreatic Neoplasms
7
Carcinoma, Squamous Cell
7
Carcinoma, Ovarian Epithelial
6
Adenocarcinoma of Lung
6
Uterine Cervical Neoplasms
5
Mouth Neoplasms
5
Mesothelioma
5
Lung Diseases
5
Laryngeal Neoplasms
5
Respiratory Tract Neoplasms
4
Interventions
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
selinexor
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
balstilimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
Carboplatin
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled